首页|期刊导航|肿瘤学与转化医学(英文)|Immune checkpoint blockade in glioblastoma:overcoming barriers through mechanism-informed,biomarker-guided,and combinatorial immunotherapies targeting the tumor microenvironment and validated by clinical trials
Immune checkpoint blockade in glioblastoma:overcoming barriers through mechanism-informed,biomarker-guided,and combinatorial immunotherapies targeting the tumor microenvironment and validated by clinical trialsOA
Immune checkpoint blockade in glioblastoma:overcoming barriers through mechanism-informed,biomarker-guided,and combinatorial immunotherapies targeting the tumor microenvironment and validated by clinical trials
Arpita Mukherjee
Shri Venkateshwara University,Gajraula,Uttar Prades,India
GlioblastomaImmune checkpoint inhibitorsTumor microenvironmentProgrammed death-1/programmed death-ligand 1Cytotoxic T-lymphocyte-associated antigen-4BiomarkersCombination therapyImmunotherapy resistance
GlioblastomaImmune checkpoint inhibitorsTumor microenvironmentProgrammed death-1/programmed death-ligand 1Cytotoxic T-lymphocyte-associated antigen-4BiomarkersCombination therapyImmunotherapy resistance
《肿瘤学与转化医学(英文)》 2026 (1)
15-37,23
评论